Rick Doblin: Psychedelics | Lex Fridman Podcast #202

Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), a seminal figure in psychedelic science and cultural history.

Author of 'One Flew Over the Cuckoo's Nest,' who wrote parts of the book under the influence of LSD, benefiting from the drug's ability to broaden associations and foster creative imagery.

Philanthropist who, through the Population Council, funded the development of RU-486, making it the first drug brought to market by a non-profit.

The founder of psychoanalysis, who considered dreams the 'royal road to the unconscious' and speculated about future chemical interventions in therapeutic processes.

An ethnobotanist and author known for his theories on psychedelics, including the concept of 'machine elves' experienced during DMT trips; seen by Doblin as an entertainer whose cultural priming influenced experiences.

The leader of Nazi Germany, mentioned in the context of Rick Doblin's personal DMT and ketamine experiences where he confronted the potential for evil within humanity.

The 'Unabomber,' allegedly part of MK-Ultra studies at Harvard, highlighting that psychedelic experiences are highly context-dependent and can lead to negative outcomes.

Physicist who noted that the splitting of the atom changed everything except our mode of thinking, implying a need for a new, more connected way of thinking.

US President who signed a bill in 1984 creating incentives for developing off-patent drugs through data exclusivity.

Philosopher and author known for his work on psychedelics and his concept of the brain as a 'reducing valve' that filters information.

Chemist known as the 'godfather of MDMA' for rediscovering and bringing it back into use, and for his work on structure-activity relationships of psychedelic molecules.

A doctor in England who conducted a study using MDMA for alcohol use disorder with promising results, often by treating underlying trauma.

The person who coined the term 'psychedelic' (mind manifesting) in dialogue with Aldous Huxley.

Psychiatrist who proposed the concept of the 'collective unconscious,' an idea that echoes the shared human experiences and information accessible through deep consciousness.

Minister at Boston University's Marsh Chapel, mentor to Martin Luther King Jr., and interested in the political implications of mystical experiences; he permitted the Good Friday Experiment to take place.

Psychologist known for his hierarchy of needs, mentioned in the context of how the mind filters information to focus on core needs.

Prominent investor and philanthropist, mentioned as a major donor to the Population Council's efforts in bringing RU-486 to market.

Chemist who invented LSD and first synthesized psilocybin, collaborator with Sasha Shulgin on structure-activity relationships in psychedelics.

An American psychologist, researcher, and counter-culture icon known for advocating psychedelic use, who spearheaded early psilocybin and LSD research at Harvard.

A doctor, formerly head of psychiatry products at the FDA, who advises MAPS on study design, particularly on reducing bias when double-blind studies are difficult.

A long-standing figure at the FDA, in charge of the Office of Science Policy, who advised MAPS on the design of their Phase 3 clinical trials.

Researcher at the Bronx VA studying the epigenetics of trauma, particularly in Holocaust survivors and their children, exploring how trauma is transmitted across generations.

Often called an empathogen or entactogen, it brings material to the surface and alters information processing, stimulating oxytocin and reducing amygdala activity while increasing prefrontal cortex activity.

A classic psychedelic found in mushrooms, known for its ego-dissolving and mystical experience-producing effects, lasting 4-6 hours.

An anesthetic approved as S-ketamine for depression, used in psychedelic doses (one-tenth the anesthetic dose) to reveal deeper information, noted for varying effects between adults and children.

An SSRI (selective serotonin reuptake inhibitor) listed as one of the approved drugs for PTSD, though noted to be less effective in men and for combat-related PTSD.

A classic psychedelic, the main active ingredient in peyote, similar to MDMA in chemical structure (phenethylamine), known for warmth and visuals.

Described as a psychedelic, closer to classic psychedelics in effect than to MDMA.

An SSRI (selective serotonin reuptake inhibitor) listed as one of the approved drugs for PTSD, though noted to be less effective in men and for combat-related PTSD.

A classic psychedelic known for ego dissolution and unitive states, lasting 8-12 hours.

A classic psychedelic brew with indigenous roots, orally active due to a combination of substances, producing effects for a couple of hours.

A toxin from the Sonoran toad, considered one of the most powerful psychedelics, known for completely dissolving ego structures and revealing deeper layers of consciousness.

An SSRI (selective serotonin reuptake inhibitor) listed as one of the approved drugs for PTSD, though noted to be less effective in men and for combat-related PTSD.

A psychedelic mentioned as crucial for opiate addiction, drawing interest from new companies for research.

The abortion pill, approved in Europe and later in the US, notable as the first drug made into a medicine by a non-profit (Population Council) in 1999.

Management consulting firm hired by MAPS Public Benefit Corporation to help plot their commercialization strategy for MDMA.

Pharmaceutical company that developed and patented S-ketamine for depression, delivered without therapy, leading to quick fading effects and maximizing profits.

The pharmaceutical company that first invented MDMA in 1912.

U.S. government agency that in the 1980s and 90s promoted a narrative that MDMA was neurotoxic and caused brain damage, a claim later largely disproven.

A non-profit pharmaceutical company founded by Rick Doblin in 1986 to research and develop psychedelics into approved medicines, and to advocate for drug policy reform.

The European regulatory agency, analogous to the FDA, that sets standards for drug approval.

The regulatory agency that approves drugs for medical use, with whom MAPS has extensively negotiated study protocols for MDMA-assisted therapy.

A powerful classic psychedelic that, when smoked, produces rapid, intense effects lasting 10-15 minutes, often described as ego-dissolving.

A study conducted by Timothy Leary aimed at reducing recidivism through psilocybin-induced mystical experiences in prisoners, later found to have fudged data.

A study led by Timothy Leary at Boston University's Marsh Chapel investigating whether psilocybin in a religious setting could produce mystical experiences in divinity students.

A novel written by Ken Kesey, parts of which were inspired by his LSD experiences, reflecting themes of mental institution control and perception.

A highly impactful medical journal where the results of MAPS' first Phase 3 MDMA-assisted therapy study for PTSD were published.

A band whose origins at Ken Kesey's 'acid tests' contributed to their improvisational style and sustained success, attributed to LSD experiences.